RecruitingNCT05546086

BeijngFH Health Cohort Study

Risk Prediction System for Metabolic Associated Fatty Liver Disease, a Community-based Cohort Study


Sponsor

Beijing Friendship Hospital

Enrollment

8,103 participants

Start Date

Apr 18, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Metabolic associated fatty liver disease(MEFLD) is a major chronic liver disease that can lead to various adverse events, such as liver cancer, cardiovascular disease, and chronic kidney disease. The present community-based cohort study enrolls subjects who take health physical examinations at the sub-center outpatient department, Beijing Friendship Hospital. Investigators collect their baseline information, including demographic data, clinical history, physical examination, laboratory results, imageological examination, and so on. Follow-up surveys are conducted annually and the information collected is the same as the baseline. The outcome information, including cardiovascular disease, malignancy, liver cirrhosis, liver decompensation, liver transplantation, and all-cause mortality, are obtained by linking to the hospital discharge database and death registration system of Beijing. The primary aim of the study is to build a risk-stratified evaluation system for MAFLD through the cohort.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Aged 18 years or older
  • Permanent residents in Beijing
  • Signing informed consent

Exclusion Criteria1

  • No

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Beijing Friendship Hospital, Capital Medical University

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05546086


Related Trials